NxClinical has very strong visualization tools which is important for cytogeneticists - a reviewer can easily view the allele patterns and estimate % aberrant cells. But NxClinical 5.0 makes this even easier by automatically performing this calculation on a per event basis. The software also uses a user-defined threshold to mark events as mosaic or not. The software looks at event-specific aberrant cell fraction using both the Log R value as well as BAF (where available). This approach uses platform-dependent scaling so that the correct calculation can be applied to samples from multiple platforms (e.g. ThermoFisher, Illumina, CNV from NGS).
The 2019 Tumor Profiling: Methods and Protocols book is out and we are particularly excited about the Whole-Genome Single Nucleotide Polymorphism Microarray for Copy Number and Loss of Heterozygosity Analysis chapter! Read more.
Cedar Sinai Medical Center in Los Angeles, CA has filed a patent for a method for prognosticating patient survival based on the ZEB1 gene. The application also describes methods for selecting therapies based on analysis of ZEB1 and several other genes.
Research advances in clinical genetics recently uncovered the causative alterations for several rare diseases. Evaluate your clinical samples with ease for copy number alteration, sequence variants or both using NxClinical 3.0.
Dr. Breen of North Carolina State University has been a long time user of our Nexus Copy Number software and we were pleased to learn of his application of his latest patent: a new, non-invasive method of diagnosing bladder cancer in dogs.
We have come a long way in a short amount of time with NGS (next-generation sequencing) technologies. Learn more about the benefits here!
Cancer samples usually contain a mixture of tumor and normal cells. Take a look at this formula for calculating a one-copy loss event.